Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Placebo-controlled Crossover Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
2019-000375-16Phase 2Terminated
- Sponsor
- BELLUS Health Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of camlipixant in refractory chronic cough (RCC) (2 arms), sponsored by BELLUS Health Inc. Primary endpoint: Change from baseline in awake cough frequency. Started Mar 2019; status: terminated.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on 2019-000375-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000375-16.